Propeller Health and Aptar Pharma have teamed up to develop a connected MDI that features an integrated sensor and an electronic dose counter. The companies say that they expect to begin clinical studies with the inhaler by the end of 2016 and that they are looking to license the device.
The Propeller inhaler tracking platform has received 510(k) clearance from the FDA and is compatible with most standard MDIs by attaching a sensor to the top of the canister. The new cMDI will include an integral sensor built into the inhaler.
Propeller CEO David Van Sickle commented, “Patients and physicians deserve better designed inhalers that are easier to use and help them successfully treat their chronic respiratory disease. We are excited to work with Aptar to bring important digital innovation to respiratory drug delivery. We expect our connected inhaler to become the cornerstone for a platform of digital programs that will support and encourage better management of and quality of life with chronic respiratory disease. Together I believe we have the scale and expertise to impact millions of patients with asthma and COPD around the world.”
Aptar Pharma President Salim Haffar said, “We are pleased to partner with Propeller to develop the next generation of connected inhalers. We believe the combination of Aptar’s expertise and technology in inhaler design and development with Propeller’s proven system for asthma and COPD patient management creates a compelling offer to meet the needs of stakeholders in this market place.”
Propeller’s platform is also approved for use with the Diskus DPI and the Respimat SMI. In December 2015, the company announced that it was developing a sensor for GSK’s Ellipta DPI.
Read the Propeller Health press release.
